We enjoyed the vibrant #bioProcessUK conference last week at @StGeorgesHallLV, Liverpool. Engaging sessions covering policy, trends and #sustainability in #lifesciences as well as many great conversations with industry contacts old and new. @BIA_UK

Great to catch up with old friends and colleagues in London this week and to make some important new connections as well. Thanks to @LSXLeaders for showcasing #Medannex at #Investival.

Excellent article by @innovateuk's Head of Medicines Dr Karen Spink highlighting the importance of putting the #child first when creating future life-changing #cancer therapies. We're proud to be part of this mission.

Just back from a fabulous #ESMO24 discussing the latest exciting updates from our first-in-human study with clinicians and collaborators. We're looking forward to sharing our #Phase1 #oncology data next year.

Thanks to @LSXLeaders for the opportunity to introduce our first-in-class #therapeutic to investors and industry colleagues at #LSXUSA in Boston, MA. We’re excited to share the very encouraging signals emerging from our ongoing Phase 1b #oncology study ('ATTAINMENT').

We're grateful for this significant grant from @innovateuk's #CancerTherapeutics programme, to prepare our first-in-class anti-#annexin-A1 therapy (MDX-124) for a clinical study in the rare childhood bone cancer, paediatric #osteosarcoma. #CancerTherapeutics #InnovateUKFunded

@ScottishLifesci @innovateuk @AngliaRuskin thanks @ScottishLifesci - onwards and upwards!

A fabulous weekend at #ASCO24 introducing the first-in-human study of MDX-124 - the first therapy to target #annexin-A1. Great to meet new contacts and long-term collaborators, including Chief Investigator Prof Dan Palmer of @livuni_LCTC. More info here:

Can't wait to unveil details of the first #clinical study (ATTAINMENT) of a therapy targeting #annexin-A1 - a new and unique #cancer target - at the world's largest oncology meeting this weekend. It's always exciting when a new class of medicine enters the clinic! #ASCO24 @ASCO

Thanks to @LSIntegrates for a vibrant and thought-provoking #BioIntegrates2024 in #Cambridge. Our Director of Scientific Operations, Dr Fiona Dempsey, thoroughly enjoyed the panel discussions, making valuable new connections and catching up with old friends and collaborators.

Great to make so many new connections at #LSXWorld in London, as we progress through the Phase 1b clinical study of our first-in-class #therapeutic. Thanks to @LSXLeaders for inviting our CEO Ian Abercrombie to speak on the #Biotech Leaders stage.

Very pleased to announce the grant of new #patents in the USA, China, Japan and Canada protecting the composition of matter of MDX-124, the first clinic-ready therapy to target #annexin-A1. Read the full story here:

On the day of the announcement that #Scotland's thriving #lifesciences sector achieved nearly £10.5 billion turnover in 2021, it was great to celebrate with industry colleagues old and new at @ScotLifeScience awards. A big thank you to @BIA_UK for hosting us.

Great to discover new developments in the field of #AntibodyDrugConjugates at the 14th @World_ADC event in London this week. It’s a pleasure to catch up with old colleagues and make new connections in this exciting area of drug development.

RT @JuliaEdgar1: @mickcraig101 and I seek applications from motivated students interested in undertaking a 4 year PhD programme in Neuroimm…

RT @oncodaily: Our recent publication unveils the potential of a ground-breaking therapeutic antibody - @husseinalali @MedannexLtd https:/…

As we strengthen our board ahead of clinical expansion, we welcome Sir @grahambradymp as a non-executive director. Currently a Member of Parliament at Westminster, Sir Graham brings a wealth of experience to Medannex as we embark on an ambitious programme of #clinicaltrials.

A great night at the @BIA_UK gala dinner yesterday. Thanks to @MedDiscCat for the invitation and the excellent company - the evening just flew by!